{"url_path":"/sec/zbio/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1953926/0001104659-26-059735-index.html","accession_number":"0001104659-26-059735","cik":"0001953926","ticker":"ZBIO","issuer_name":"Zenas BioPharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1953926/0001104659-26-059735-index.html","primary_entity_key":"0001953926","primary_entity_name":"Zenas BioPharma, Inc."},"word_count":73,"has_tables":true,"body_markdown":"Item 5. Other Information\n\nRule 10b5-1 Trading Plans\n\nDuring our fiscal quarter ended March 31, 2026, no director or “officer” (as defined in Rule 16a-1(f) under the Exchange Act) of the Company entered into, modified or terminated contracts, instructions or written plans for the purchase or sale of our common stock that are intended to satisfy the affirmative defense conditions specified in Rule 10b5-1(c) under the Exchange Act.\n\n​\n\n51\n\n[Table of Contents](#TOC)"}